Back to Stakeholders
Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchCollaborative Research Consortia
Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations
Care Delivery & Psychedelic Facilitation
Research, Drug Development & Manufacturing

University Health Network, Toronto

Canada
8 Trials

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

Academic Research

0 papers

Published Papers

0

Trial Involvement

8

Distinct Focus Topics

0

Latest Publication

Unknown

Entity type: Research Centre / Institute

Network Scope

Hospital-network model with affiliated research institutes and multi-program collaborations.

Connected Research Organizations

University of Toronto

Collaboration Notes

Large academic health network with university-linked research programs, including psychiatric and translational collaborations.

Collaboration Info

Quick Facts

Type
Other
HQ
Canada
Website
Visit

Sponsored Trials

7
Not yet recruitingII

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer (PEARL-C1)

Start Date
Compounds
Psilocybin
RecruitingI

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression (Psilo-BD)

Start Date
Compounds
Psilocybin
RecruitingII

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Start Date
Compounds
Psilocybin
RecruitingII

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)

Start Date
Compounds
Psilocybin
RecruitingII

i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial (Ket-CBT)

Start Date
Compounds
Ketamine, Placebo
RecruitingIII

Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

Start Date
Compounds
Ketamine, Placebo
CompletedII

Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

Start Date
Compounds
Ketamine

Collaborated Trials

1
Temporarily not availableIII

Ketamine Versus Electroconvulsive Therapy in Depression

Start Date
Compounds
Ketamine, Placebo